A computational evaluation of FDA medicines’ ability to inhibit hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for acute respiratory distress syndrome

COVID-19 infection is associated with a significant fatality rate in individuals suffering from severe acute respiratory distress syndrome (ARDS). Among the several possibilities, inhibition of hypoxia-inducible factor prolyl hydroxylase-2 or prolyl hydroxylase domain-containing protein 2 (PHD2) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Jaikanth, Balasubramaniam, Jayasudha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282623/
https://www.ncbi.nlm.nih.gov/pubmed/35855326
http://dx.doi.org/10.1007/s11224-022-02012-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282623/
https://www.ncbi.nlm.nih.gov/pubmed/35855326
http://dx.doi.org/10.1007/s11224-022-02012-z

Ejemplares similares